Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of upadacitinib in non-segmental vitiligo
MOH_2024-01-10_013176Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vitiligo comparing Upadacitinib with Placebo to upadacitinib (2 arms). Primary endpoints: Adverse events and Change in disease activity. Started Jan 2024; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on MOH_2024-01-10_013176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-10_013176.